journal article·2025-08-04

Bioengineering strategies to optimize STING agonist therapy

Pere Dosta, Alexander M. Cryer, Michaela Prado, Natalie Artzi

Nature Reviews Bioengineering· Volume 3· Issue 8
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: interferon and immune responses · Viral Infections and Vectors · vaccines and immunoinformatics approaches

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Amarante-Mendes, G. P. et al. Pattern recognition receptors and the host cell death molecular machinery. Front. Immunol. 9, 2379 (2018).10.3389/fimmu.2018.02379 ↗
2. Paludan, S. R. & Bowie, A. G. Immune sensing of DNA. Immunity 38, 870–880 (2013).10.1016/j.immuni.2013.05.004 ↗
3. Jiang, M. et al. cGAS-STING, an important pathway in cancer immunotherapy. J. Hematol. Oncol. 13, 81 (2020).10.1186/s13045-020-00916-z ↗
4. Flood, B. A., Higgs, E. F., Li, S., Luke, J. J. & Gajewski, T. F. STING pathway agonism as a cancer therapeutic. Immunol. Rev. 290, 24–38 (2019).10.1111/imr.12765 ↗
5. Kwon, J. & Bakhoum, S. F. The cytosolic DNA-sensing cGAS–STING pathway in cancer. Cancer Discov. 10, 26–39 (2020).10.1158/2159-8290.CD-19-0761 ↗
6. Civril, F. et al. Structural mechanism of cytosolic DNA sensing by cGAS. Nature 498, 332–337 (2013).10.1038/nature12305 ↗
7. Kranzusch, P. J., Lee, A. S., Berger, J. M. & Doudna, J. A. Structure of human cGAS reveals a conserved family of second-messenger enzymes in innate immunity. Cell Rep. 3, 1362–1368 (2013).10.1016/j.celrep.2013.05.008 ↗
8. Li, X. et al. Cyclic GMP-AMP synthase is activated by double-stranded DNA-induced oligomerization. Immunity 39, 1019–1031 (2013).10.1016/j.immuni.2013.10.019 ↗
9. Zhang, X. et al. The cytosolic DNA sensor cGAS forms an oligomeric complex with DNA and undergoes switch-like conformational changes in the activation loop. Cell Rep. 6, 421–430 (2014).10.1016/j.celrep.2014.01.003 ↗
10. Xie, W. et al. Human cGAS catalytic domain has an additional DNA-binding interface that enhances enzymatic activity and liquid-phase condensation. Proc. Natl Acad. Sci. USA 116, 11946–11955 (2019).10.1073/pnas.1905013116 ↗
11. DeFilippis, V. R. et al. Interferon regulatory factor 3 is necessary for induction of antiviral genes during human cytomegalovirus infection. J. Virol. 80, 1032–1037 (2006).10.1128/JVI.80.2.1032-1037.2006 ↗
12. Wu, J., Dobbs, N., Yang, K. & Yan, N. Interferon-independent activities of mammalian STING mediate antiviral response and tumor immune evasion. Immunity 53, 115–126.e5 (2020).10.1016/j.immuni.2020.06.009 ↗
13. Liu, T., Zhang, L., Joo, D. & Sun, S.-C. NF-κB signaling in inflammation. Signal Transduct. Target. Ther. 2, 17023 (2017).10.1038/sigtrans.2017.23 ↗
14. Ishikawa, H., Ma, Z. & Barber, G. N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461, 788–792 (2009).10.1038/nature08476 ↗
15. Cao, X. et al. Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance. Nat. Commun. 12, 5866 (2021).10.1038/s41467-021-26112-2 ↗
16. Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405–414 (2015).10.1038/nri3845 ↗
17. Kuka, M., De Giovanni, M. & Iannacone, M. The role of type I interferons in CD4+ T cell differentiation. Immunol. Lett. 215, 19–23 (2019).10.1016/j.imlet.2019.01.013 ↗
18. Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 638–652 (2014).10.1016/j.ccell.2014.09.007 ↗
19. Schiavoni, G., Mattei, F. & Gabriele, L. Type I interferons as stimulators of DC-mediated cross-priming: impact on anti-tumor response. Front. Immunol. 4, 483 (2013).10.3389/fimmu.2013.00483 ↗
20. Barber, G. N. STING: infection, inflammation and cancer. Nat. Rev. Immunol. 15, 760–770 (2015).10.1038/nri3921 ↗
21. Kennedy, R. B. et al. Polymorphisms in STING affect human innate immune responses to poxviruses. Front. Immunol. https://doi.org/10.3389/fimmu.2020.567348 (2020).10.3389/fimmu.2020.567348 ↗
22. Lohinai, Z. et al. Loss of STING expression is prognostic in non-small cell lung cancer. J. Surg. Oncol. 125, 1042–1052 (2022).10.1002/jso.26804 ↗
23. Lee, K. M. et al. Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple-negative breast cancer. Cancer Immunol. Res. 10, 829–843 (2022).10.1158/2326-6066.CIR-21-0826 ↗
24. Low, J. T. et al. Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition. Cancer Cell 40, 439–440 (2022).10.1016/j.ccell.2022.04.009 ↗
25. Xia, T., Konno, H., Ahn, J. & Barber, G. N. Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and correlates with tumorigenesis. Cell Rep. 14, 282–297 (2016).10.1016/j.celrep.2015.12.029 ↗
26. Kuhl, N. et al. STING agonism turns human T cells into interferon-producing cells but impedes their functionality. EMBO Rep. 24, e55536 (2023).10.15252/embr.202255536 ↗
27. Gulen, M. F. et al. cGAS–STING drives ageing-related inflammation and neurodegeneration. Nature 620, 374–380 (2023).10.1038/s41586-023-06373-1 ↗
28. Jacquelot, N. et al. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res. 29, 846–861 (2019).10.1038/s41422-019-0224-x ↗
29. Mellman, I., Chen, D. S., Powles, T. & Turley, S. J. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity 56, 2188–2205 (2023).10.1016/j.immuni.2023.09.011 ↗
30. Knelson, E. H. et al. Activation of tumor-cell STING primes NK-cell therapy. Cancer Immunol. Res. 10, 947–961 (2022).10.1158/2326-6066.CIR-22-0017 ↗
31. Lu, L. et al. STING signaling promotes NK cell antitumor immunity and maintains a reservoir of TCF-1+ NK cells. Cell Rep. 42, 113108 (2023).10.1016/j.celrep.2023.113108 ↗
32. Sauer, J. D. et al. The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect. Immun. 79, 688–694 (2011).10.1128/IAI.00999-10 ↗
33. Fuertes, M. B. et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J. Exp. Med. 208, 2005–2016 (2011).10.1084/jem.20101159 ↗
34. Lam, K. C. et al. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell 184, 5338–5356.e21 (2021).10.1016/j.cell.2021.09.019 ↗
35. Burnette, B. C. et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res. 71, 2488–2496 (2011).10.1158/0008-5472.CAN-10-2820 ↗
36. Vatner, R. E. & Janssen, E. M. STING, DCs and the link between innate and adaptive tumor immunity. Mol. Immunol. 110, 13–23 (2019).10.1016/j.molimm.2017.12.001 ↗
37. Yang, H. et al. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J. Clin. Investig. 129, 4350–4364 (2019).10.1172/JCI125413 ↗
38. Nicolai, C. J. et al. NK cells mediate clearance of CD8+ T cell–resistant tumors in response to STING agonists. Sci. Immunol. 5, eaaz2738 (2020).10.1126/sciimmunol.aaz2738 ↗
39. Zhang, C. X. et al. STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion. Cell Death Differ. 26, 2314–2328 (2019).10.1038/s41418-019-0302-0 ↗
40. Wang, Q. et al. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nat. Commun. 13, 3022 (2022).10.1038/s41467-022-30568-1 ↗
41. Ohkuri, T., Kosaka, A., Nagato, T. & Kobayashi, H. Effects of STING stimulation on macrophages: STING agonists polarize into “classically” or “alternatively” activated macrophages? Hum. Vaccines Immunother. 14, 285–287 (2018).10.1080/21645515.2017.1395995 ↗
42. Chen, S. et al. Macrophages in immunoregulation and therapeutics. Signal Transduct. Target. Ther. 8, 207 (2023).10.1038/s41392-023-01452-1 ↗
43. Chelvanambi, M., Fecek, R. J., Taylor, J. L. & Storkus, W. J. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. J. ImmunoTher. Cancer 9, e001906 (2021).10.1136/jitc-2020-001906 ↗
44. Wang-Bishop, L. et al. STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy. Sci. Immunol. 8, eadd1153 (2023).10.1126/sciimmunol.add1153 ↗
45. Kohli, K., Pillarisetty, V. G. & Kim, T. S. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 29, 10–21 (2022).10.1038/s41417-021-00303-x ↗
46. Hoch, T. et al. Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy. Sci. Immunol. 7, eabk1692 (2022).10.1126/sciimmunol.abk1692 ↗
47. Wang, L. et al. STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells. Cell Death Dis. 15, 265 (2024).10.1038/s41419-024-06638-1 ↗
48. Berger, G. et al. STING activation promotes robust immune response and NK cell–mediated tumor regression in glioblastoma models. Proc. Natl Acad. Sci. USA 119, e2111003119 (2022).10.1073/pnas.2111003119 ↗
49. Gulley, J. L. et al. Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment. J. Natl Cancer Inst. 109, djw261 (2017).10.1093/jnci/djw261 ↗
50. Vanderlugt, C. L. & Miller, S. D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2, 85–95 (2002).10.1038/nri724 ↗
51. Walker, M. M., Crute, B. W., Cambier, J. C. & Getahun, A. B cell–intrinsic STING signaling triggers cell activation, synergizes with b cell receptor signals, and promotes antibody responses. J. Immunol. 201, 2641–2653 (2018).10.4049/jimmunol.1701405 ↗
52. Li, S. et al. STING-induced regulatory B cells compromise NK function in cancer immunity. Nature 610, 373–380 (2022).10.1038/s41586-022-05254-3 ↗
53. Salvagno, C. et al. Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response. Nat. Cell Biol. 21, 511–521 (2019).10.1038/s41556-019-0298-1 ↗
54. Wang, C. et al. Ultrasound-responsive low-dose doxorubicin liposomes trigger mitochondrial DNA release and activate cGAS-STING-mediated antitumour immunity. Nat. Commun. 14, 3877 (2023).10.1038/s41467-023-39607-x ↗
55. Shen, J. et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 79, 311–319 (2019).10.1158/0008-5472.CAN-18-1003 ↗
56. Hayman, T. J. et al. STING enhances cell death through regulation of reactive oxygen species and DNA damage. Nat. Commun. 12, 2327 (2021).10.1038/s41467-021-22572-8 ↗
57. Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843–852 (2014).10.1016/j.immuni.2014.10.019 ↗
58. Lv, J. et al. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nat. Med. 29, 1424–1436 (2023).10.1038/s41591-023-02369-6 ↗
59. Nakajima, S. et al. Radiation-induced remodeling of the tumor microenvironment through tumor cell-intrinsic expression of cGAS-STING in esophageal squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 115, 957–971 (2023).10.1016/j.ijrobp.2022.10.028 ↗
60. Carozza, J. A. et al. Extracellular cGAMP is a cancer-cell-produced immunotransmitter involved in radiation-induced anticancer immunity. Nat. Cancer 1, 184–196 (2020).10.1038/s43018-020-0028-4 ↗
61. Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51–72 (2013).10.1146/annurev-immunol-032712-100008 ↗
62. Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Immunogenic cell stress and death. Nat. Immunol. 23, 487–500 (2022).10.1038/s41590-022-01132-2 ↗
63. Carideo Cunniff, E. et al. TAK-676: a novel stimulator of interferon genes (STING) agonist promoting durable IFN-dependent antitumor immunity in preclinical studies. Cancer Res. Commun. 2, 489–502 (2022).10.1158/2767-9764.CRC-21-0161 ↗
64. Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N. & Tarsounas, M. Targeting DNA damage response pathways in cancer. Nat. Rev. Cancer 23, 78–94 (2023).10.1038/s41568-022-00535-5 ↗
65. Zhou, S. et al. Engineering cGAS-agonistic oligonucleotides as therapeutics for cancer immunotherapy. Mol. Ther. Nucleic Acids 35, 102126 (2024).10.1016/j.omtn.2024.102126 ↗
66. Liu, H. et al. Pharmacological boosting of cGAS activation sensitizes chemotherapy by enhancing antitumor immunity. Cell Rep. 42, 112275 (2023).10.1016/j.celrep.2023.112275 ↗
67. Laursen, M. F. et al. CD11c-targeted delivery of DNA to dendritic cells leads to cGAS- and STING-dependent maturation. J. Immunother. 41, 9–18 (2018).10.1097/CJI.0000000000000195 ↗
68. Wang, C. et al. Manganese increases the sensitivity of the cGAS-STING pathway for double-stranded DNA and is required for the host defense against DNA viruses. Immunity 48, 675–687.e7 (2018).10.1016/j.immuni.2018.03.017 ↗
69. Smith, J. A. STING, the endoplasmic reticulum, and mitochondria: is three a crowd or a conversation? Front. Immunol. 11, 611347 (2020).10.3389/fimmu.2020.611347 ↗
70. Petrasek, J. et al. STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease. Proc. Natl Acad. Sci. USA 110, 16544–16549 (2013).10.1073/pnas.1308331110 ↗
71. McKnight, K. L. et al. Stimulator of interferon genes (STING) is an essential proviral host factor for human rhinovirus species A and C. Proc. Natl Acad. Sci. USA 117, 27598–27607 (2020).10.1073/pnas.2014940117 ↗
72. Danilchanka, O. & Mekalanos, J. J. Cyclic dinucleotides and the innate immune response. Cell 154, 962–970 (2013).10.1016/j.cell.2013.08.014 ↗
73. Ross, P. et al. Regulation of cellulose synthesis in Acetobacter xylinum by cyclic diguanylic acid. Nature 325, 279–281 (1987).10.1038/325279a0 ↗
74. Wu, J. et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339, 826–830 (2013).10.1126/science.1229963 ↗
75. Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786–791 (2013).10.1126/science.1232458 ↗
76. Wang, H. et al. cGAS is essential for the antitumor effect of immune checkpoint blockade. Proc. Natl Acad. Sci. USA 114, 1637–1642 (2017).10.1073/pnas.1621363114 ↗
77. Guo, J. et al. Distinct dynamic and conformational features of human STING in response to 2′3′-cGAMP and c-di-GMP. ChemBioChem 20, 1838–1847 (2019).10.1002/cbic.201900051 ↗
78. Zhang, X. et al. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol. Cell 51, 226–235 (2013).10.1016/j.molcel.2013.05.022 ↗
79. Corrales, L. et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 11, 1018–1030 (2015).10.1016/j.celrep.2015.04.031 ↗
80. Wang, S. et al. ENPP1 is an innate immune checkpoint of the anticancer cGAMP–STING pathway in breast cancer. Proc. Natl Acad. Sci. USA 120, e2313693120 (2023).10.1073/pnas.2313693120 ↗
81. Wang, Z. & Xi, Z. Chemical evolution of cyclic dinucleotides: perspective of the analogs and their preparation. Tetrahedron 87, 132096 (2021).10.1016/j.tet.2021.132096 ↗
82. Chang, W. et al. Discovery of MK-1454: a potent cyclic dinucleotide stimulator of interferon genes agonist for the treatment of cancer. J. Med. Chem. 65, 5675–5689 (2022).10.1021/acs.jmedchem.1c02197 ↗
83. Meric-Bernstam, F. et al. Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoural STING agonist, in patients with advanced/metastatic solid tumors or lymphomas. Clin. Cancer Res. 28, 677–688 (2022).10.1158/1078-0432.CCR-21-1963 ↗
84. Calvo, E. et al. 1030P phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors. Ann. Oncol. 34, S626 (2023).
85. Kim, D. S. et al. E7766, a macrocycle-bridged stimulator of interferon genes (STING) agonist with potent pan-genotypic activity. ChemMedChem 16, 1740–1743 (2021).
86. Luke, J. J. et al. Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors. J. ImmunoTher. Cancer 13, e010511 (2025).10.1136/jitc-2024-010511 ↗
87. Vyskocil, S. et al. Identification of novel carbocyclic pyrimidine cyclic dinucleotide STING agonists for antitumor immunotherapy using systemic intravenous route. J. Med. Chem. 64, 6902–6923 (2021).10.1021/acs.jmedchem.1c00374 ↗
88. Diamond, J. R. et al. Phase 1a/1b study design of the novel STING agonist, immune-stimulating antibody-conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors. J. Clin. Oncol. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS2690 (2022).10.1200/JCO.2022.40.16_suppl.TPS2690 ↗
89. Bukhalid, R. A. et al. XMT-2056, a HER2-directed STING agonist antibody–drug conjugate, induces innate antitumor immune responses by acting on cancer cells and tumor-resident immune cells. Clin. Cancer Res. 31, 1766–1782 (2025).10.1158/1078-0432.CCR-24-2449 ↗
90. Soomer-James, J., Damelin, M. & Malli, N. Abstract 4423: XMT-2056, a HER2-targeted STING agonist antibody-drug conjugate, exhibits ADCC function that synergizes with STING pathway activation and contributes to anti-tumor responses. Cancer Res. https://doi.org/10.1158/1538-7445.AM2023-4423 (2023).10.1158/1538-7445.AM2023-4423 ↗
91. Janku, F. et al. A phase Ia/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors. J. Clin. Oncol. https://doi.org/10.1200/JCO.2020.38.15_suppl.TPS3162 (2020).10.1200/JCO.2020.38.15_suppl.TPS3162 ↗
92. Ramanjulu, J. M. et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature 564, 439–443 (2018).10.1038/s41586-018-0705-y ↗
93. Kelly, C. M. et al. Phase I trial of CRD3874-SI, a systemically administered STING agonist, in patients with advanced solid tumors. J. Clin. Oncol. https://doi.org/10.1200/JCO.2023.41.16_suppl.9120 (2024).10.1200/JCO.2023.41.16_suppl.9120 ↗
94. Liu, B. et al. Human STING is a proton channel. Science 381, 508–514 (2023).10.1126/science.adf8974 ↗
95. Chin, E. N. et al. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science 369, 993–999 (2020).10.1126/science.abb4255 ↗
96. Pan, B.-S. et al. An orally available non-nucleotide STING agonist with antitumor activity. Science 369, eaba6098 (2020).10.1126/science.aba6098 ↗
97. Allen, B. K. et al. Design of a systemic small molecule clinical STING agonist using physics-based simulations and artificial intelligence. Preprint at bioRxiv https://doi.org/10.1101/2022.05.23.493001 (2022).10.1101/2022.05.23.493001 ↗
98. Caldwell, S. E., Janosko, C. P. & Deiters, A. Development of a light-activated STING agonist. Org. Biomol. Chem. 22, 302–308 (2024).10.1039/D3OB01578E ↗
99. Huayamares, S. G., Loughrey, D., Kim, H., Dahlman, J. E. & Sorscher, E. J. Nucleic acid-based drugs for patients with solid tumours. Nat. Rev. Clin. Oncol. 21, 407–427 (2024).10.1038/s41571-024-00883-1 ↗
100. Simonsen, J. B. Lipid nanoparticle-based strategies for extrahepatic delivery of nucleic acid therapies – challenges and opportunities. J. Control. Release 370, 763–772 (2024).10.1016/j.jconrel.2024.04.022 ↗